Credit: Getty Images Researchers assessed patients with uncomplicated urinary tract infections to determine factors associated with extended-spectrum β-lactamase-producing uropathogens.

Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...

An international study led by a Rutgers scientist comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially ...

Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) have become a critical global public health challenge due to their high resistance to β-lactam antibiotics and association with severe ...

An international study led by a Rutgers scientist comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially ...

Credit: Getty Images. The Infectious Diseases Society of America aimed to develop up-to-date guidance focusing on the treatment of antimicrobial-resistant gram-negative infections. The Infectious ...

The Biomedical Advanced Research and Development Authority (BARDA) in the US will support Basilea’s development of a new type of oral antibiotic to treat complicated urinary tract infections (cUTIs).